疼痛管理治療の市場規模、シェア、成長分析、薬剤クラス別、適応症別、流通チャネル別、地域別 - 産業予測、2025～2032年

疼痛管理治療の世界市場規模は、2023年に787億米ドルと評価され、予測期間中（2025-2032年）にCAGR 3.6%で成長し、2024年の815億3,000万米ドルから2032年には1,082億米ドルに成長する見通しです。

2023年10月現在、疼痛管理の状況は、医療分野におけるその重要性の認識の高まりを反映しています。線維筋痛症、神経障害性疼痛、術後の不快感などの慢性的な症状を含め、さまざまな種類の疼痛に対して患者のQOLを高める集学的アプローチを実施するため、疼痛医学の専門医を頼る医師が増えています。疼痛管理治療の人気が高まっているのは、幅広い医療問題に対応していることからも明らかです。しかし、政府予算の削減や製薬スポンサーからの支援の減少により、疼痛擁護団体の影響力や財源が減少しているため、市場は課題に直面しています。これらの団体は歴史的に疼痛管理イニシアチブを推進する上で重要な役割を果たしてきたため、この動向は市場成長の潜在的なハードルとなります。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次データと一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制情勢
• ケーススタディ
• 技術分析
• 特許分析

疼痛管理治療市場規模：薬剤クラス別

• 市場概要
• NSAIDs
• 麻酔薬
• 抗けいれん薬
• 片頭痛治療薬
• 抗うつ薬
• オピオイド
• 非麻薬性鎮痛剤
• その他

疼痛管理治療市場規模：適応症別

• 市場概要
• 関節炎の痛み
• 神経障害性疼痛
• がんの痛み
• 慢性腰痛
• 術後の痛み
• 片頭痛
• 線維筋痛症
• 筋肉の捻挫
• 骨折
• 急性虫垂炎
• その他

疼痛管理治療市場規模：流通チャネル別

• 市場概要
• オンライン薬局
• 病院薬局
• 小売薬局

疼痛管理治療市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 市場の最近の動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 会社概要
  • 製品ポートフォリオ分析
  • セグメント別シェア分析
  • 収益の前年比比較（2022-2024）

主要企業プロファイル

• CSL Behring（Australia）
• Takeda Pharmaceutical Company Limited（Japan）
• Pharming Group N.V.（Netherlands）
• BioCryst Pharmaceuticals, Inc.（USA）
• Ionis Pharmaceuticals, Inc.（USA）
• Sanofi S.A.（France）
• Adverum Biotechnologies, Inc.（USA）
• KalVista Pharmaceuticals, Inc.（USA）
• Attune Pharmaceuticals, Inc.（USA）
• Arrowhead Pharmaceuticals, Inc.（USA）
• Amgen Inc.（USA）
• BioMarin Pharmaceutical Inc.（USA）
• Catalyst Biosciences, Inc.（USA）
• RUCONEST（Pharming Group N.V., Netherlands）
• Haegarda（CSL Limited, Australia）
• Firazyr（Shire plc, UK）
• Shire plc（UK）
• Dyax Corp.（USA）
• Adverum Biotechnologies, Inc.（USA）
• Amgen Inc.（USA）

結論と推奨事項

Global Pain Management Therapeutics Market size was valued at USD 78.7 billion in 2023 and is poised to grow from USD 81.53 billion in 2024 to USD 108.2 billion by 2032, growing at a CAGR of 3.6% during the forecast period (2025-2032).

As of October 2023, the landscape of pain management reflects a growing recognition of its importance within the medical field. Physicians increasingly turn to pain medicine specialists to implement multidisciplinary approaches that enhance patient quality of life across various types of pain, including chronic conditions like fibromyalgia, neuropathic pain, and post-operative discomfort. The rising popularity of pain management therapeutics is evident as they cater to a wide spectrum of medical issues. However, the market faces challenges as pain advocacy organizations experience diminishing influence and financial resources due to government funding cuts and decreased support from pharmaceutical sponsors. This trend poses a potential hurdle for market growth as these organizations have historically played a crucial role in advancing pain management initiatives.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pain Management Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pain Management Therapeutics Market Segmental Analysis

Global Pain Management Therapeutics Market is segmented by Drug Class, Indication, Distribution channel and region. Based on Drug Class, the market is segmented into NSAIDs, Anesthetics, Anticonvulsants, Anti-migraine Agents, Antidepressants, Opioids, Nonnarcotic Analgesics and Others. Based on Indication, the market is segmented into Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, Fibromyalgia, Muscle Sprain/Strain, Bone Fracture, Acute Appendicitis and Others. Based on Distribution channel, the market is segmented into Online Pharmacy, Hospital Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pain Management Therapeutics Market

The global pain management therapeutics market is experiencing significant growth due to the increasing prevalence of various medical conditions that lead to pain and discomfort, such as ulcers, osteoarthritis, chronic arthritis, multiple sclerosis, cancer, and diabetic neuropathy. These conditions necessitate effective treatments for both acute and chronic pain, driving demand for pain management solutions. As patients seek relief from their ailments, the preference for advanced pain management therapeutics rises, further fueling market expansion. Consequently, the collective urgency to address pain-related issues across diverse populations is a crucial factor contributing to the market's robust development.

Restraints in the Global Pain Management Therapeutics Market

The growth of the Global Pain Management Therapeutics market is anticipated to be hindered by the issue of prescription drug abuse. Many individuals consume prescribed medications in a manner that deviates from medical guidance, often underestimating the potential dangers associated with such behavior. This misuse not only poses significant health risks but can also result in severe consequences, including fatal outcomes. As awareness of these dangers increases, it may lead to stricter regulations and more cautious prescribing practices, ultimately curbing the expansion of the market. Consequently, addressing the challenges posed by prescription misuse is crucial for sustainable market growth.

Market Trends of the Global Pain Management Therapeutics Market

The Global Pain Management Therapeutics market is witnessing a significant trend towards personalized medicine, with a growing focus on biologics and rapid-acting lifestyle therapies, which currently represent over 70% of all medications under development. This shift is driven by advancements in pharmacogenomics and an increased understanding of individual pain mechanisms, leading to targeted treatments that enhance efficacy and reduce side effects. Additionally, the rising prevalence of chronic pain conditions and a growing aging population are fueling demand for innovative therapies, positioning personalized approaches as a key driver in the evolution of pain management strategies globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis
• Patent Analysis

Global Pain Management Therapeutics Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• NSAIDs
• Anesthetics
• Anticonvulsants
• Anti-migraine Agents
• Antidepressants
• Opioids
• Nonnarcotic Analgesics
• Others

Global Pain Management Therapeutics Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Arthritic Pain
• Neuropathic Pain
• Cancer Pain
• Chronic Back Pain
• Postoperative Pain
• Migraine
• Fibromyalgia
• Muscle Sprain/Strain
• Bone Fracture
• Acute Appendicitis
• Others

Global Pain Management Therapeutics Market Size by Distribution channel & CAGR (2025-2032)

• Market Overview
• Online Pharmacy
• Hospital Pharmacy
• Retail Pharmacy

Global Pain Management Therapeutics Market Size & CAGR (2025-2032)

• North America (Drug Class, Indication, Distribution channel)
  • US
  • Canada
• Europe (Drug Class, Indication, Distribution channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Distribution channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Distribution channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Distribution channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• CSL Behring (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharming Group N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioCryst Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ionis Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KalVista Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Attune Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Arrowhead Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMarin Pharmaceutical Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalyst Biosciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RUCONEST (Pharming Group N.V., Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Haegarda (CSL Limited, Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Firazyr (Shire plc, UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shire plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dyax Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Adverum Biotechnologies, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations